HRP20021039B1 - Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja - Google Patents

Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Info

Publication number
HRP20021039B1
HRP20021039B1 HR20021039A HRP20021039A HRP20021039B1 HR P20021039 B1 HRP20021039 B1 HR P20021039B1 HR 20021039 A HR20021039 A HR 20021039A HR P20021039 A HRP20021039 A HR P20021039A HR P20021039 B1 HRP20021039 B1 HR P20021039B1
Authority
HR
Croatia
Prior art keywords
optionally substituted
halogen
independently selected
ora
heteroaryl
Prior art date
Application number
HR20021039A
Other languages
English (en)
Inventor
Labelle Marc
Sturino Claudio
Roy Bruno
Berthelette Carl
Boyd Michael
Lachance Nicolas
Scheigetz John
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Publication of HRP20021039A2 publication Critical patent/HRP20021039A2/hr
Publication of HRP20021039B1 publication Critical patent/HRP20021039B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Abstract

Spoj formule I: i njegove farmaceutski prihvatljive soli, njihovi hidrati i esteri, naznačeni time, da su: R1, R2 i R3 svaki neovisno odabrani od grupe koja se sastoji od: (1) vodika, i (2) RC,R4 i R5 su svaki neovisno odabrani od grupe koja se sastoji od: (1) H, (2) F, (3) CN, (4) C1-6alkil, (5) ORa, i (6) S(O)nC1-6alkil, gdje je svaki od spomenutih alkil grupa opcionalno supstituirana s halogenom, iliR4 i R5 na istom ugljikovom atomu mogu predstavljati okso, ili R4 i R5 na istom ugljikovom atomu ili na susjednim ugljikovim atomima uzeti zajedno formiraju 3- ili 4- člani prsten, koji sadržava 0 ili 1 heteroatom, odabran od N, S, ili O opcionalno supstituiran s jednom ili dvije grupe odabrane od F, CF3 i CH3;R6 je odabran od grupe koja se sastoji od: d)H, (2)C1-6alkil opcionalno supstituiran s jednom do šest grupa neovisnoodabranima od ORa i halogena, i (3)heterociklil opcionalno supstituiran s jednim do četiri halogena; ili R5 i R6 vezani na susjednim ugljikovim atomima zajedno formiraju 3- ili 4- člani prsten, koji sadržava 0 ili 1 heteroatoma, odabranih od N, S, ili O, opcionalno supstituiran s jednom ili dvije grupe odabrane od F, CF3 i CH3;X je odabran od grupe koja se sastoji od: C=O, SO2, i C1-4alkil, gdje je spomenuti alkil opcionalno supstituiran s jednim do šest halogena; Ar je aril ili heteroaril, svaki opcionalno supstituiran s jednom do četiri grupe, neovisno odabrane od RC;Q je C1-6alkil, opcionalno supstituiran s jednom do šest grupa, neovisno odabranim od: (1) halogen, (2) aril, (3) heteroaril, (4) OH, (5) OC1-6alkil, (6) COOH, (7) CONRaRb, (8) C(O)NSO2R7, (9) tetrazolil, gdje aril, heteroaril i alkil su svaki opcionalno supstituirani s jednom do šest grupa, neovisno odabranim od halogena, CF3, i COOH; iliQ i R6 zajedno formiraju 3- ili 4-člani prsten koji opcionalno sadržava heteroatom odabran od N, S, i O, te je opcionalno supstituiran s jednom ili dvije grupe neovisno odabrane od: (1) halogen, (2) okso, (3) ORa, (4) COOH, (5) C(O)NHSO2R7, i (6) tetrazolil, R7 je odabran od grupe koja se sastoji od: (1) C1-6alkil opcionalno supstituiran s jednim do šest halogena, (2) aril, i (3) heteroaril, gdje su spomenuti aril i heteroaril opcionalno supstituirani s halogenom, OC1-5alkil, C1-5alkil i gdje je spomenuti alkil opcionalno supstituiran s jednim do šest halogena; Ra i Rb su neovisno odabrani od vodika i C1-6alkil opcionalno supstituiran s jednim do šest halogena; Rc je (1) halogen, (2) CN, (3) C1-6alkil opcionalno supstituirana s jednom do šest grupa neovisno odabranih od halogena, NRaRb, C(O)Ra, C(ORa)RaRb, i ORa (4) C2-6alkenil opcionalno supstituiran s jednom do šest grupa neovisno odabranih od halogena i ORa, (5) heterociklil, (6) aril, (7) heteroaril, (8) C(O)Ra, (9) C(ORa)RaRb (10) C(O)ORa, (11) CONRaRb, (12) OCONRaRb, (13) S(O)nR7 (14) NRaC(O)OC1-6, gdje je alkil opcionalno supstituiran s jednim do šest halogena i (15) S(O)nNRaRb,gdje su heterociklil, aril, heteroaril opcionalno supstituirani s jednom do četiri grupe, neovis
HR20021039A 2000-07-25 2002-12-30 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja HRP20021039B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (2)

Publication Number Publication Date
HRP20021039A2 HRP20021039A2 (en) 2004-10-31
HRP20021039B1 true HRP20021039B1 (hr) 2011-03-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20021039A HRP20021039B1 (hr) 2000-07-25 2002-12-30 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Country Status (34)

Country Link
US (1) US6410583B1 (hr)
EP (1) EP1305286B1 (hr)
JP (1) JP4119745B2 (hr)
KR (1) KR100746814B1 (hr)
CN (1) CN1214007C (hr)
AT (1) ATE284388T1 (hr)
AU (2) AU2001277430B2 (hr)
BG (1) BG66084B1 (hr)
BR (1) BR0112756A (hr)
CA (1) CA2416867C (hr)
CZ (1) CZ2003236A3 (hr)
DE (1) DE60107687T2 (hr)
DK (1) DK1305286T3 (hr)
DZ (1) DZ3402A1 (hr)
EA (1) EA006765B1 (hr)
EC (1) ECSP034428A (hr)
EE (1) EE05287B1 (hr)
ES (1) ES2231526T3 (hr)
GE (1) GEP20053595B (hr)
HK (1) HK1058934A1 (hr)
HR (1) HRP20021039B1 (hr)
HU (1) HUP0301745A3 (hr)
IL (2) IL153406A0 (hr)
IS (1) IS2170B (hr)
MX (1) MXPA03000710A (hr)
NO (1) NO325011B1 (hr)
NZ (1) NZ523106A (hr)
PL (1) PL207342B1 (hr)
PT (1) PT1305286E (hr)
RS (1) RS50491B (hr)
SK (1) SK287507B6 (hr)
UA (1) UA73787C2 (hr)
WO (1) WO2002008186A2 (hr)
ZA (1) ZA200300554B (hr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031196A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CN1791577A (zh) * 2003-05-20 2006-06-21 麦克弗罗斯特加拿大有限公司 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
AU2004247285A1 (en) * 2003-06-12 2004-12-23 Merck Frosst Canada Ltd Cycloalkanepyrrolopyridines as DP receptor antagonists
AU2004262970B2 (en) * 2003-08-07 2010-03-18 Merck Sharp & Dohme Limited Treatment for Alzheimer's disease and related conditions
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2006008118A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2603757A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
KR20180023049A (ko) 2008-07-23 2018-03-06 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
CN105816453B (zh) * 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
AU2009295308A1 (en) * 2008-09-25 2010-04-01 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
EP2387405A2 (en) 2009-01-13 2011-11-23 ProteoSys AG Pirenzepine as an agent in cancer treatment
JP2013508339A (ja) 2009-10-26 2013-03-07 バイエル・クロップサイエンス・アーゲー ４−［［（６−クロロピリジン−３−イル）メチル］（２，２−ジフルオロエチル）アミノ］フラン−２（５ｈ）−オンの新規固体形態
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
SG11202002065VA (en) 2017-09-13 2020-04-29 Progenity Inc Preeclampsia biomarkers and related systems and methods
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
KR20210074291A (ko) 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173A (zh) * 2021-04-30 2022-11-01 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
EP0837052B1 (en) * 1995-06-21 2006-08-23 Shionogi & Co., Ltd. Bicyclic amino derivatives and pgd 2 antagonist containing the same
NZ336143A (en) * 1996-12-13 2002-05-31 Shionogi & Co Benzothiophenecarboxamide derivatives and pgd 2 antagonists comprising them
ATE295183T1 (de) * 1998-06-03 2005-05-15 Shionogi & Co Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Also Published As

Publication number Publication date
RS50491B (sr) 2010-03-02
DK1305286T3 (da) 2005-03-14
EA200300171A1 (ru) 2003-06-26
HK1058934A1 (en) 2004-06-11
BR0112756A (pt) 2003-06-24
CZ2003236A3 (cs) 2003-05-14
DZ3402A1 (fr) 2002-01-31
EP1305286A2 (en) 2003-05-02
IS2170B (is) 2006-11-15
EE200300033A (et) 2004-10-15
HUP0301745A3 (en) 2010-03-29
ECSP034428A (es) 2003-03-10
DE60107687D1 (de) 2005-01-13
PL207342B1 (pl) 2010-12-31
BG66084B1 (bg) 2011-03-31
IL153406A (en) 2008-03-20
US6410583B1 (en) 2002-06-25
CA2416867A1 (en) 2002-01-31
ZA200300554B (en) 2004-04-23
JP4119745B2 (ja) 2008-07-16
KR20030024810A (ko) 2003-03-26
WO2002008186A3 (en) 2002-03-21
EA006765B1 (ru) 2006-04-28
HUP0301745A2 (hu) 2003-09-29
CN1214007C (zh) 2005-08-10
GEP20053595B (en) 2005-08-10
PT1305286E (pt) 2005-04-29
EP1305286B1 (en) 2004-12-08
WO2002008186A2 (en) 2002-01-31
KR100746814B1 (ko) 2007-08-06
YU97902A (sh) 2006-05-25
NO325011B1 (no) 2008-01-14
HRP20021039A2 (en) 2004-10-31
NO20030374D0 (no) 2003-01-24
UA73787C2 (en) 2005-09-15
ES2231526T3 (es) 2005-05-16
CN1443165A (zh) 2003-09-17
AU2001277430B2 (en) 2006-05-25
PL363168A1 (en) 2004-11-15
CA2416867C (en) 2008-03-25
JP2004504380A (ja) 2004-02-12
SK932003A3 (en) 2003-06-03
AU7743001A (en) 2002-02-05
NZ523106A (en) 2005-01-28
MXPA03000710A (es) 2003-06-04
IS6655A (is) 2002-12-12
BG107438A (bg) 2003-09-30
NO20030374L (no) 2003-01-24
SK287507B6 (sk) 2010-12-07
DE60107687T2 (de) 2005-12-01
IL153406A0 (en) 2003-07-06
EE05287B1 (et) 2010-04-15
ATE284388T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
HRP20021039B1 (hr) Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja
DE69501947T2 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
RS51888B (en) N- (PHENYL (PIPERIDIN-2-IL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY
DE60025938D1 (de) Triphenylalkenderivate und ihre anwendung als selektive modulatoren des östrogenrezeptors
RS50519B (sr) Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona
ME00564A (hr) Derivati (tio) karbamoil-cikloheksana kao antagonisti d3/d2 receptora
RS52134B (sr) Modulatori receptora glukokortikoida
HRP20080236T3 (hr) Kinolinski derivati kao inhibitori fosfodiesteraze
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
HUP9903758A2 (hu) Benzoxazinon dopamin D4 receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
HRP20070498T3 (hr) Derivati indanil piperazina, postupak njihove priprave i farmaceutske smjese koje ih sadrže
SE7602122L (sv) Nya piperazinyliminorifamyciner och sett att framstella desamma
HUP9900584A2 (hu) Új benzoil-guanidin-származékok, eljárás előállításukra és gyógyszerkészítmények előállításában való felhasználásuk
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
FI942928A (fi) Fenyleenidialkanoaattien aromaattiset esterit ihmisen neutrofiili-elastaasin inhibiittoreina
RS50432B (sr) Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže
HRP20000878B1 (hr) Kemijska sinteza derivata morfolina
CO4920251A1 (es) Compuestos hexahidro 1 h. -pirrolizina 7 a. -heterociclico- substituidos utiles en el control de la transmision sinaptica quimica
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
DK1471059T3 (da) 2,4,6-tris(dineopentyl-4'-aminobenzalmalonat)-s-triazin, fotobeskyttende kosmetiske sammensætninger indeholdende denne forbindelse og anvendelse af den nævnte forbindelse
YU44592A (sh) Derivati 4-aril-3-(heteroarilkarbamido) hinolina
DE69311500D1 (de) 2,3-Diphenyl-5-pyrrolyl-furan Derivate, Verfahren und Zwischenprodukte für ihre Herstellung und ihre Verwendung als entzündungshemmende, antiallergische und blutplättchenaggregationshemmende Mittel
ES8105704A1 (es) Procedimiento de preparacion de nuevos eteres oximas, de sussales de adicion acidas y de sus derivados amonicos cuater- narios
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
DE3866292D1 (de) Piperazinylalkylpiperazindion-derivate, ihre verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130716

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20140723